ArticleJournal of primary care & community health
Serum Albumin as a Biomarker of Brain and Microvascular Health in Older Adults: Implications for Community-Based Aging Research.
Article in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentifying circulating biomarkers that reflect cerebrovascular health may help clarify underlying mechanisms associated with brain damage. Serum albumin, a multifunctional protein with antioxidant, anti-inflammatory, and endothelial-stabilizing properties, could serve as a marker of cerebral integrity. We examined the association between albumin levels and neuroimaging markers of cerebral small vessel disease (cSVD) in a rural population of older adults.
methodsWe conducted a cross-sectional study among community-dwelling individuals aged ≥ 60 years in rural Ecuador. Participants were invited to undergo brain MRI and laboratory testing as part of the study protocol. Inclusion was based on completion of these procedures and serum albumin levels within the physiological range of 3.0-5.0 g/dL. Logistic regression models were fitted to assess the association between serum albumin and cSVD markers, adjusting for demographics and cardiovascular health metrics .
resultsAmong 409 participants (mean age: 66.2 ± 6.1 years; 60% women), moderate-to-severe white matter hyperintensities (WMH) were present in 34% of participants. Serum albumin showed a non-linear inverse association with WMH. Only participants in the highest albumin quartile (4.42-5.0 g/dL) showed significantly lower odds of moderate-to-severe WMH (adjusted OR: 0.48; 95% CI: 0.25-0.93). No significant associations emerged with other cSVD markers.
conclusionHigher physiological albumin levels were associated with a lower burden of WMH, consistent with a threshold-dependent protective effect on the cerebral microvasculature. These findings support serum albumin as a candidate biomarker of brain health in aging populations. Albumin may capture systemic processes - such as endothelial integrity and vascular inflammation - that contribute to cSVD. Its accessibility and affordability underscore its potential utility in community-based aging research and population-level screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.